Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.
Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China.
The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020.
Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 7, 24 | -0.04 Increased by +97.84% | - |
| May 14, 24 | -0.05 Increased by +97.67% | - |
| Feb 14, 24 | -0.24 Increased by +88.75% | - |
| Nov 13, 23 | -1.83 Increased by +47.71% | -0.58 Decreased by -215.52% |
| Sep 18, 23 | -1.95 Increased by +64.55% | -1.05 Decreased by -85.71% |
| May 11, 23 | -1.94 Increased by +64.73% | -0.19 Decreased by -921.05% |
| Feb 14, 23 | -2.10 Increased by +65.00% | -3.16 Increased by +33.54% |
| Nov 9, 22 | -3.50 Increased by +58.82% | -0.18 Decreased by -1.84 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 76.00 K Increased by +N/A% | -2.51 M Increased by +15.43% | Decreased by -3.30 K% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.32 M Increased by +30.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.01 M Increased by +37.68% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -1.02 M Increased by +69.99% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.96 M Increased by +34.69% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.33 M Increased by +38.49% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.23 M Increased by +39.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.41 M Increased by +42.15% | Decreased by N/A% Decreased by N/A% |